Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects

Trial Profile

Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects

Discontinued
Phase of Trial: Phase III

Latest Information Update: 01 Sep 2017

At a glance

  • Drugs Bococizumab (Primary)
  • Indications Angina pectoris; Atherosclerosis; Cardiovascular disorders; Myocardial infarction; Stroke
  • Focus Registrational; Therapeutic Use
  • Acronyms SPIRE-1
  • Sponsors Pfizer
  • Most Recent Events

    • 17 Jun 2017 This trial has been completed in Denmark (end date: 22 Mar 2017).
    • 10 Jun 2017 Biomarkers information updated
    • 18 May 2017 This trial has been completed in Sweden (end date: 22 Mar 2017).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top